No Data
No Data
Express News | Cellectar Biosciences Partners With City Of Hope Cancer Center To Focus On Clinical Development Of Cellectar's Lead Radioconjugate Asset, Iopofosine I 131, In Mycosis Fungoides; Initiation Is Planned For Late 2024 Or Early 2025
Express News | Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
Express News | Cellectar Biosciences Files $300M Mixed Securities Shelf
Express News | Cellectar Biosciences Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing
Buy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug Pipeline
Q1 2024 Cellectar Biosciences Inc Earnings Call
No Data